Imikeraderm (Imiquimod)

Imiquimod activates Toll‑like receptor 7 on immune cells in the skin, leading to the release of cytokines such as interferon‑α and interleukins. This cytokine surge enhances both innate and adaptive immunity, producing antiviral and antitumor effects directly at the site of application.

The dosing regimen for Imikeraderm is determined by the prescribing clinician based on the specific indication, lesion size, and patient factors. Healthcare providers set the frequency and duration of application, and patients should follow the written instructions precisely.

Safety data for Imikeraderm in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Imikeraderm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other topical agents such as podophyllotoxin or sinecatechins, Imikeraderm uses an immune‑modulating mechanism rather than direct antiviral activity. This can lead to longer treatment courses but may provide higher clearance rates for extensive or recurrent warts, especially when other therapies have failed.

Imikeraderm should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture and direct sunlight to maintain its stability and potency.

Imikeraderm is applied topically to clean, dry skin. A thin layer is spread over the prescribed area using clean hands or a gloved finger, usually once daily or as directed by the prescriber. The treated skin should be left uncovered unless instructed otherwise.

Serious risks include severe allergic reactions such as angioedema or anaphylaxis, extensive skin ulceration, and secondary bacterial infections. Patients should seek immediate medical attention if they experience rapid swelling, difficulty breathing, or persistent, worsening lesions.

Imikeraderm is contraindicated in individuals with known hypersensitivity to imiquimod or any excipients, and it should be avoided on broken or severely inflamed skin. Patients with compromised immune systems should only use it under specialist supervision.